What's Happening?
Omeros Corporation announced its financial results for the third quarter ended September 30, 2026, highlighting significant growth in YARTEMLEA sales. The company's lead complement inhibitor, YARTEMLEA (narsoplimab-wuug),
which treats stem cell transplant-associated thrombotic microangiopathy (TA-TMA), generated gross revenue of $41.8 million, a 30% increase from the second quarter of 2026. Net revenue also rose by 26% to $35.9 million. Omeros reported a GAAP net loss of $57.4 million, primarily due to non-cash mark-to-market adjustments, but achieved a non-GAAP adjusted net income of $4.7 million. The company also generated positive operating cash flow of $13.3 million in the quarter and repurchased $30.5 million of its 2029 Notes, reducing potential share dilution.
Why It's Important?
The strong financial performance of Omeros, particularly the growth in YARTEMLEA sales, is important for the U.S. biopharmaceutical sector and patients with rare diseases. YARTEMLEA is the first and only approved treatment for TA-TMA, an often-lethal complication of stem cell transplantation. The increase in sales indicates growing adoption and access to this critical therapy. The New Technology Add-on Payment (NTAP) status for YARTEMLEA, effective October 1, 2026, is expected to significantly reduce hospitals' net treatment costs and improve patient access by providing up to $287,079 in additional Medicare reimbursement per eligible inpatient case. This financial support mechanism is crucial for rare disease treatments, which often come with high costs, ensuring that innovative therapies reach patients who need them.
What's Next?
Omeros plans to continue investing in field education to promote earlier recognition of TA-TMA and timely treatment with YARTEMLEA. The company is also working to expand patient access through international regulatory approvals and named-patient programs. In the U.S., Omeros is educating transplant centers on YARTEMLEA's reimbursement advantages, including the NTAP and favorable Medicare outpatient reimbursement for 340B-acquired YARTEMLEA starting January 1, 2027. Beyond YARTEMLEA, Omeros is advancing its pipeline, with clinical studies for YARTEMLEA in ARDS and TA-TMA prevention expected to begin soon, and the Phase 2 clinical program for its long-acting MASP-2 inhibitor OMS1029. The company also anticipates milestone payments from Novo Nordisk for zaltenibart, further funding its research and development efforts.
Beyond the Headlines
The success of YARTEMLEA and the implementation of NTAP status highlight the complex interplay between pharmaceutical innovation, regulatory frameworks, and healthcare economics in the U.S. for rare diseases. The NTAP program is designed to incentivize the development and adoption of new technologies, but it also underscores the financial challenges associated with bringing specialized treatments to market. The European Medicines Agency's (EMA) negative opinion on narsoplimab for TA-TMA, despite its U.S. approval, points to differing regulatory standards and market access hurdles across regions. This divergence can impact global development strategies for biopharmaceutical companies and the availability of treatments for patients worldwide. Omeros's broader pipeline, focusing on endothelial injury, complement-mediated diseases, cancers, and addictive disorders, demonstrates a strategic approach to leveraging its scientific platforms for diverse medical needs.








